| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| Other Sizes |
| Targets |
The specific molecular targets of Leucocianidol have not been fully characterized, but as a flavonoid, it is known to interact with various cellular targets and signaling pathways. Flavonoids are known for their antioxidant properties, which are mediated through the direct scavenging of free radicals and the modulation of antioxidant enzyme activities. Leucocianidol may also interact with inflammatory signaling pathways, such as NF-κB and MAPK, to exert anti-inflammatory effects. Its anti-ulcerogenic activity may involve the protection of gastric mucosa through the enhancement of mucus production, reduction of gastric acid secretion, or inhibition of the inflammatory response. The compound's potential use in the treatment of hemorrhoids may be related to its vasoprotective and anti-inflammatory effects. However, the specific molecular targets of Leucocianidol require further investigation.
|
|---|---|
| ln Vitro |
In vitro, Leucocianidol has been studied for its antioxidant and anti-inflammatory activities. The compound exhibits free radical scavenging activity, as measured by DPPH and ABTS assays. It also inhibits the production of pro-inflammatory cytokines in activated immune cells. In addition, Leucocianidol has been shown to have cytoprotective effects in various cell types, protecting against oxidative stress-induced cell damage. Its anti-ulcerogenic effects have been studied in gastric cell lines, where it protects against aspirin-induced cell damage and reduces the production of inflammatory mediators. However, specific in vitro data on Leucocianidol's potency and mechanisms are limited.
|
| ln Vivo |
When taken daily, leucocyanidin (5 mg) can effectively prevent stomach erosion caused by aspirin in individuals at risk of Wistar who weigh between 250 and 330 grams on average [1].
In vivo, Leucocianidol has demonstrated anti-ulcerogenic activity in rat models. In aspirin-induced gastric ulcer models, oral administration of Leucocianidol significantly reduces the number and severity of gastric erosions. The compound's protective effects are associated with the preservation of gastric mucosal integrity and the reduction of inflammatory cell infiltration. In addition, Leucocianidol has been studied for its effects on hemorrhoids, showing improvements in symptoms such as bleeding and inflammation. Its potential use in non-alcoholic fatty liver disease (NAFLD) has also been explored, with preliminary studies suggesting that it may reduce hepatic lipid accumulation and inflammation. However, comprehensive in vivo studies are needed to fully characterize the compound's pharmacological profile. |
| Enzyme Assay |
The non-cellular assay for Leucocianidol would likely involve the measurement of its antioxidant activity using cell-free systems. The compound's ability to scavenge free radicals is assessed using DPPH, ABTS, or FRAP assays. In these assays, the compound is incubated with the radical solution, and the decrease in absorbance is measured. The IC50 for radical scavenging is determined. In addition, the compound's ability to inhibit lipid peroxidation can be measured using the thiobarbituric acid reactive substances (TBARS) assay. These standard assays are commonly used to evaluate the antioxidant activity of flavonoids.
|
| Cell Assay |
The cellular assay for Leucocianidol involves treating cultured cells with the compound and measuring its effects on oxidative stress, inflammation, or cell viability. For antioxidant activity, cells are pre-treated with Leucocianidol and then exposed to an oxidative stress inducer (such as H₂O₂ or rotenone). Intracellular ROS levels are measured using fluorescent probes such as DCFH-DA. For anti-inflammatory activity, cells are stimulated with LPS, and the production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) is measured by ELISA. Cell viability is assessed using standard assays. In gastric cell models, the compound's protective effects against aspirin-induced damage are evaluated by measuring cell viability and the release of lactate dehydrogenase (LDH).
|
| Animal Protocol |
The in vivo animal studies for Leucocianidol typically use the aspirin-induced gastric ulcer model in rats. Rats are fasted overnight and then administered aspirin orally to induce gastric mucosal damage. Leucocianidol is administered orally at various doses (typically 10-100 mg/kg) prior to or concurrently with aspirin. After a defined period, the stomachs are removed, and the gastric mucosa is examined for the number and severity of erosions. The ulcer index is calculated. In addition, gastric tissue samples are collected for histopathological examination and for measurement of inflammatory markers (such as myeloperoxidase activity and cytokine levels). The compound's anti-ulcerogenic activity is compared to that of standard drugs, such as omeprazole or misoprostol.
|
| ADME/Pharmacokinetics |
Leucocianidol has a molecular weight of 306.27 g/mol and a molecular formula of C₁₅H₁₄O₇. It is a flavonoid compound that is soluble in organic solvents and has limited aqueous solubility. The compound should be stored in a cool, dry place, protected from light, as flavonoids can be light-sensitive. Its pharmacokinetic properties, including oral bioavailability and metabolism, have not been extensively characterized.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Leucocianidol has not been extensively characterized. As a naturally occurring flavonoid, it is generally considered to have low toxicity, but comprehensive toxicology studies are lacking. The compound should be handled with appropriate laboratory safety precautions.
|
| References | |
| Additional Infomation |
Leucocianidol (Leucocyanidin) is a naturally occurring flavonoid with anti-ulcerogenic, antioxidant, and potential vasoprotective properties. It is found in various plant sources, including horse chestnut seeds and unripe plantain bananas. The compound has been studied for its potential therapeutic applications in the treatment of hemorrhoids, gastric ulcers, and non-alcoholic fatty liver disease. Its anti-ulcerogenic activity has been demonstrated in rat models, showing significant protection against aspirin-induced gastric erosions. Leucocianidol continues to be a subject of research for its pharmacological properties and potential health benefits.
|
| Molecular Formula |
C15H14O7
|
|---|---|
| Molecular Weight |
306.27
|
| Exact Mass |
306.074
|
| CAS # |
480-17-1
|
| Related CAS # |
(+)-Leucocyanidin;69256-15-1
|
| PubChem CID |
445881
|
| Appearance |
White to off-white solid powder
|
| Density |
1.709 g/cm3
|
| Boiling Point |
641.5ºC at 760 mmHg
|
| Flash Point |
341.8ºC
|
| Vapour Pressure |
2.46E-17mmHg at 25°C
|
| Index of Refraction |
1.78
|
| LogP |
1.037
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
22
|
| Complexity |
392
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
OC1C=CC(C2OC3=CC(=CC(O)=C3C(O)C2O)O)=CC=1O
|
| InChi Key |
SBZWTSHAFILOTE-NOYMGPGASA-N
|
| InChi Code |
InChI=1S/C15H14O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,13-21H/t13?,14-,15+/m0/s1
|
| Chemical Name |
(2R,3S)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,4,5,7-tetrol
|
| Synonyms |
Vitamin P faktor Resivit Leucocianidol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~326.51 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.16 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.16 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2651 mL | 16.3255 mL | 32.6509 mL | |
| 5 mM | 0.6530 mL | 3.2651 mL | 6.5302 mL | |
| 10 mM | 0.3265 mL | 1.6325 mL | 3.2651 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
